Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Status: Recruiting
Phase: Phase 2
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT01953926 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-615

 

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification.

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Massachusetts General Hospital

Overall PI:
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Site-responsible Investigators:
James Mier, MD, Beth Israel Deaconess Medical Center
Dejan Juric, MD, Massachusetts General Hospital

Contacts:
Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060
Dana-Farber Cancer Institute: Andrew Wolanski, 617-632-6623, andrew_wolanski@dfci.harvard.edu
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Histologically confirmed cancers for which no curative therapy exists. - Documented HER2 mutation. Exclusion Criteria: - Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib, neratinib). - Patients who are receiving any other anticancer agents. - Symptomatic or unstable brain metastases. - Women who are pregnant or breast-feeding. Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients


    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us
award

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.

award

Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters